In vivo self-assembled siRNAs targeting VEGFR2 and mTOR for renal cell carcinoma treatment

Jinyu Fu , Xinyan Zhou , Junjie Mi , Likun Zhou , Luzhen Ma , Jingwei Guo , Jieqiong Lei , Shuang Qu , Zheng Fu , Tianyao Liu , Xi Chen , Rong Yang

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101126

PDF (6512KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101126 DOI: 10.1016/j.ajps.2026.101126
Research Article
research-article
In vivo self-assembled siRNAs targeting VEGFR2 and mTOR for renal cell carcinoma treatment
Author information +
History +
PDF (6512KB)

Abstract

Renal cell carcinoma (RCC) is a challenging urologic malignancy characterized by its aggressive nature, including invasion, metastasis, and treatment resistance. To explore multi-targeted therapies, we established an advanced clear cell renal cell carcinoma (ccRCC) model via orthotopic tumor transplantation in mice, and established another model simulating post-surgical recurrence by performing radical nephrectomy. We engineered a genetic circuit to reprogram the host liver as a bioreactor, enabling the production and delivery of in vivo self-assembled siRNAs (IVSA-siRNAs) for co-targeting VEGFR2 and mTOR. The efficacy and toxicity of this IVSA-siRNA system were evaluated and compared with the combination therapy of sunitinib and everolimus. In the established models, the combination therapy of sunitinib and everolimus showed efficacy but induced severe adverse effects. In contrast, IVSA-siRNAs potently silenced VEGFR2 and mTOR expression, achieving therapeutic effects in both advanced and radical nephrectomy ccRCC models without discernible toxicity.

Keywords

Renal cell carcinoma / Small extracellular vesicle / Combination therapy / VEGFR2, MTOR

Cite this article

Download citation ▾
Jinyu Fu, Xinyan Zhou, Junjie Mi, Likun Zhou, Luzhen Ma, Jingwei Guo, Jieqiong Lei, Shuang Qu, Zheng Fu, Tianyao Liu, Xi Chen, Rong Yang. In vivo self-assembled siRNAs targeting VEGFR2 and mTOR for renal cell carcinoma treatment. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101126 DOI:10.1016/j.ajps.2026.101126

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.

[2]

Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 2019; 2(6): 708-15.

[3]

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers 2017; 3: 17009.

[4]

Veeratterapillay R, Simren R, El-Sherif A, Johnson MI, Soomro N, Heer R. Accuracy of the revised 2010 TNM classification in predicting the prognosis of patients treated for renal cell cancer in the north east of England. J Clin Pathol 2012; 65(4): 367-71.

[5]

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 2022; 82(4): 399-410.

[6]

Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 2014; 349: g4797.

[7]

Luciani LG, Porpiglia F, Cai T, D’Elia C, Vattovani V, Giusti G, et al. Operative safety and oncologic outcome of laparoscopic radical nephrectomy for renal cell carcinoma >7 cm: a multicenter study of 222 patients. Urology 2013; 81(6): 1239-44.

[8]

Verhoest G, Couapel JP, Oger E, Rioux-Leclercq N, Pignot G, Patard JJ, et al. Safety and feasibility of laparoscopic nephrectomy for big tumors (≥ 10 cm): a retrospective multicentric study. Clin Genitourin Cancer 2016; 14(4): e335-40.

[9]

Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, et al. A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer 2022; 127(6): 1051-60.

[10]

Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, et al. A phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). Fut Oncol 2019; 15(19): 2203-9.

[11]

Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23(9): 1133-44.

[12]

Allison SJ. Kidney cancer: targeting metabolism in RCC. Nat Rev Nephrol 2017; 13(6): 320.

[13]

Sciarra A, Cattarino S, Salciccia S, Alfarone A, Gentilucci A, Parente U, et al. The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol 2012; 81(2): 151-62.

[14]

Hakozaki T, Okuma Y, Omori M, Hosomi Y. Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett 2019; 17(3): 2946-52.

[15]

Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol 2022; 8(3): 420-44.

[16]

Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm 2020; 3(4): e181 2022.

[17]

Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13(4): 209-27.

[18]

Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60(4): 222-43.

[19]

Granovetter M. Multitarget pharmacological inhibition for renal cell carcinoma. Lancet Oncol 2016; 17(4): e140.

[20]

Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2023; 22(3): 213-34.

[21]

Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 2012; 17(17-18): 1044-52.

[22]

Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009; 61(13): 1203- 13.

[23]

Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the children’s oncology group. J Clin Oncol 2007; 25(15): 2057-62.

[24]

Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60(3): 166-93.

[25]

Molina AM, Lin X, Korytowsky B, Matczak E, Lechuga MJ, Wiltshire R, et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer 2014; 50(2): 351-8.

[26]

Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370(18): 1769-70.

[27]

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32(25): 2765-72.

[28]

Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012; 118(7): 1868-76.

[29]

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16(15): 1473-82.

[30]

Matsubara N, Naito Y, Nakano K, Fujiwara Y, Ikezawa H, Yusa W, et al. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: a phase 1 study. Int J Urol 2018; 25(11): 922-8.

[31]

Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, et al. Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma. Int J Mol Sci 2017; 18(8): 1736.

[32]

Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7(1): 24-7.

[33]

Turgutalp B, Kizil C. Multi-target drugs for Alzheimer’s disease. Trends Pharmacol Sci 2024; 45(7): 628-38.

[34]

Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong M, et al. Research priorities for an HIV cure: international AIDS Society global scientific strategy 2021. Nat Med 2021; 27(12): 2085-98.

[35]

Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30(7): 679-92.

[36]

Two-drug cocktail active against RCC. Cancer Discov 2019; 9(1): 6.

[37]

Sokolov AV, Dostdar SA, Attwood MM, Krasilnikova AA, Ilina AA, Nabieva AS, et al. Brain cancer drug discovery: clinical trials, drug classes, targets, and combinatorial therapies. Pharmacol Rev 2021; 73(4): 1-32.

[38]

Kim YD, Park TE, Singh B, Maharjan S, Choi YJ, Choung PH, et al. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Nanomedicine (Lond) 2015; 10(7): 1165-88.

[39]

Lee RC, Feinbaum RL. Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843-54.

[40]

Zhou X, Yu M, Ma L, Fu J, Guo J, Lei J, et al. In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis. Nat Commun 2022; 13(1): 5700.

[41]

Tang W, Chen Y, Jang HS, Hang Y, Jogdeo CM, Li J, et al. Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury. J Control Release 2022; 341: 300-13.

[42]

Kanvinde S, Kulkarni T, Deodhar S, Bhattacharya D, Dasgupta A. Non-viral vectors for delivery of nucleic acid therapies for cancer. BioTech (Basel) 2022; 11(1): 6.

[43]

Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell 2022; 185(15): 2806-27.

[44]

Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol 2009; 157(2): 153-65.

[45]

Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther 2017; 25(7): 1467-75.

[46]

van der Meel R, Wender PA, Merkel OM, Lostalé-Seijo I, Montenegro J, Miserez A, et al. Next-generation materials for nucleic acid delivery. Nat Rev Mater 2025; 10(7): 490-9.

[47]

Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology 2023; 21(1): 381.

[48]

Fu Z, Zhang X, Zhou X, Ur-Rehman U, Yu M, Liang H, et al. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics. Cell Res 2021; 31(6): 631-48.

[49]

Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell 2019; 177(2): 428-45.

[50]

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018; 7(1): 1535750.

[51]

Price M, Wu CC, Genshaft S, Sadow PM, Xie L, Shepard JO, et al. Imaging and management of intrathoracic renal cell carcinoma metastases. AJR Am J Roentgenol 2018; 210(6): 1181-91.

[52]

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370(9604): 2011-19.

[53]

Zhao Q, Zhang T, Xiao XR, Huang JF, Wang Y, Gonzalez FJ, et al. Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. Br J Pharmacol 2019; 176(13): 2162-78.

[54]

Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2009; 2(1): 15-25.

[55]

Kokuho N, Terasaki Y, Kunugi S, Saito Y, Urushiyama H, Terasaki M, et al. Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of rapamycin inhibitor-induced lung disease. Lab Invest 2019; 99(6): 853-65.

[56]

Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005; 54(1): 53-61.

[57]

Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 2016; 17(10): 611-25.

[58]

Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10(10): 1735-7.

[59]

Lan J, Sun L, Xu F, Liu L, Hu F, Song D, et al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res 2019; 79(1): 146-58.

[60]

Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, et al. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 2017; 171(2): 372-84.

[61]

Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012; 56(5): 1946-57.

[62]

Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun 2015; 6: 7321.

[63]

Jeong JH, Ojha U, Lee YM. Pathological angiogenesis and inflammation in tissues. Arch Pharm Res 2021; 44(1): 1-15.

[64]

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-56.

[65]

Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resist Updat 2023; 67: 100929.

[66]

Kang H, Ga YJ, Kim SH, Cho YH, Kim JW, Kim C, et al. Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges. J Biomed Sci 2023; 30(1): 88.

[67]

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther 2020; 5(1): 101.

[68]

Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013; 12(11): 967-77.

[69]

Navani V, Heng DYC. Immunotherapy in renal cell carcinoma. Lancet Oncol 2023; 24(11): 1164-6.

[70]

Patel A, Cohen S, Moret R, Maresh G, Gobe GC, Li L. Patient-derived xenograft models to optimize kidney cancer therapies. Transl Androl Urol 2019; 8(Suppl 2): S156-65.

[71]

Wiedmeier JE, Noel P, Lin W, Von Hoff DD, Han H. Single-cell sequencing in precision medicine. Cancer Treat Res 2019; 178: 237-52.

[72]

Park JH, Feroze AH, Emerson SN, Mihalas AB, Keene CD, Cimino PJ, et al. A single-cell based precision medicine approach using glioblastoma patient-specific models. NPJ Precis Oncol 2022; 6(1): 55.

PDF (6512KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉